Sung Hye Eun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sung Hye Eun has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jung Min Bae
The Catholic University of Korea
5 shared publications - Hyun Jeong Ju
Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea
2 shared publications - Ji Hae Lee
Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea
2 shared publications Chong Won Choi
Department of Dermatology, Seoul National University Hospital, Seoul, Korea
1 shared publicationG.M. Kim
Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publicationGyong Moon Kim
Department of Dermatology, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 34 (2) , 144-160
Liquid Nitrogen Spray Cooling for Reducing Injection Pain: A Pilot Study
Lee JH, et al. Ann Dermatol. 2022 Apr;34(2):144-160. https://doi.org/10.5021/ad.2022.34.2.144
- 1 January 2022
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 34 (2) , 144-160
Open AccessLiquid Nitrogen Spray Cooling for Reducing Injection Pain: A Pilot Study
Lee JH, et al. Ann Dermatol. 2022 Apr;34(2):144-160. https://doi.org/10.5021/ad.2022.34.2.144
- 2 March 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (5) , 464-469
Micropigmentation for vitiligo on light to moderately colored skin: Updated evidence from a clinical and animal study
Micropigmentation, also termed medical tattooing, can be a useful alternative treatment for patients with vitiligo who are resistant to conventional treatments. To assess the benefits and risks of micropigmentation in the treatment of refractory vitiligo, 25 lesions of 14 patients with vitiligo (Fitzpatrick skin types III and IV) were subjected to micropigmentation using an electric tattooing machine between December 2018 and March 2019. The procedure was repeated until satisfactory results were obtained. Treatment response was assessed by color matching of the treated lesion and surrounding skin using a 4‐point scale (poor, fair, good and excellent). Excellent color matching was achieved in 80% (20/25) of cases after a median of three (range, 1–5) treatment sessions. Procedure‐associated pain was considerable, but no anesthetic injection was needed. Immediate erythema and swelling were noticed after each procedure, but resolved within a few days. Overall, the treatment was tolerable. This study was limited by a small sample, no control group and a short follow‐up period. This study revealed that micropigmentation was beneficial for patients with refractory vitiligo who had light to moderately colored skin. Pigment selection, implantation depth and selection of body parts amenable to treatment were critical.
- 2 March 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (5) , 464-469
Micropigmentation for vitiligo on light to moderately colored skin: Updated evidence from a clinical and animal study
Micropigmentation, also termed medical tattooing, can be a useful alternative treatment for patients with vitiligo who are resistant to conventional treatments. To assess the benefits and risks of micropigmentation in the treatment of refractory vitiligo, 25 lesions of 14 patients with vitiligo (Fitzpatrick skin types III and IV) were subjected to micropigmentation using an electric tattooing machine between December 2018 and March 2019. The procedure was repeated until satisfactory results were obtained. Treatment response was assessed by color matching of the treated lesion and surrounding skin using a 4‐point scale (poor, fair, good and excellent). Excellent color matching was achieved in 80% (20/25) of cases after a median of three (range, 1–5) treatment sessions. Procedure‐associated pain was considerable, but no anesthetic injection was needed. Immediate erythema and swelling were noticed after each procedure, but resolved within a few days. Overall, the treatment was tolerable. This study was limited by a small sample, no control group and a short follow‐up period. This study revealed that micropigmentation was beneficial for patients with refractory vitiligo who had light to moderately colored skin. Pigment selection, implantation depth and selection of body parts amenable to treatment were critical.
- 9 August 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 485-486
Low‐fluence fractional CO 2 laser in the treatment of idiopathic guttate hypomelanosis: a pilot study
- 9 August 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 485-486
Low‐fluence fractional CO 2 laser in the treatment of idiopathic guttate hypomelanosis: a pilot study
- 31 July 2019
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 32 (6) , 864-865
Excimer stamp test distinguishing between nevus depigmentosus and segmental vitiligo
- 31 July 2019
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 32 (6) , 864-865
Excimer stamp test distinguishing between nevus depigmentosus and segmental vitiligo
- 31 March 2017
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (8) , 909-913
Increased risk of comorbid rheumatic disorders in vitiligo patients: A nationwide population‐based study
Vitiligo is a common acquired depigmentation disorder. Previous studies have shown that vitiligo is associated with a variety of autoimmune disorders. However, a large‐scale epidemiological study focused on comorbid rheumatic disorders has not been undertaken. To clarify the associations between vitiligo and various rheumatic disorders, we performed a cross‐sectional study using data from the Korean National Health Insurance claims database. Between 2009 and 2013, totals of 86 210 patients with vitiligo and 172 420 age‐ and sex‐matched controls without vitiligo were enrolled in this study. Vitiligo patients were found to be at increased risk of systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome and rheumatoid arthritis, but no significant association was found between vitiligo and dermatomyositis/polymyositis, Behçet's disease or ankylosing spondylitis. Subgroup analysis showed an increased risk of dermatomyositis/polymyositis in male and ankylosing spondylitis in female vitiligo patients. The risks of dermatomyositis/polymyositis or ankylosing spondylitis were higher in young vitiligo patients. Our study confirms a significant association between vitiligo and rheumatic disorders. Differences in comorbid rheumatic disorders by age group and sex suggest the need for patient‐specific approaches. Careful consideration of rheumatic disorders is required for the proper management of comorbidities in vitiligo patients.
- 31 March 2017
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (8) , 909-913
Increased risk of comorbid rheumatic disorders in vitiligo patients: A nationwide population‐based study
Vitiligo is a common acquired depigmentation disorder. Previous studies have shown that vitiligo is associated with a variety of autoimmune disorders. However, a large‐scale epidemiological study focused on comorbid rheumatic disorders has not been undertaken. To clarify the associations between vitiligo and various rheumatic disorders, we performed a cross‐sectional study using data from the Korean National Health Insurance claims database. Between 2009 and 2013, totals of 86 210 patients with vitiligo and 172 420 age‐ and sex‐matched controls without vitiligo were enrolled in this study. Vitiligo patients were found to be at increased risk of systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome and rheumatoid arthritis, but no significant association was found between vitiligo and dermatomyositis/polymyositis, Behçet's disease or ankylosing spondylitis. Subgroup analysis showed an increased risk of dermatomyositis/polymyositis in male and ankylosing spondylitis in female vitiligo patients. The risks of dermatomyositis/polymyositis or ankylosing spondylitis were higher in young vitiligo patients. Our study confirms a significant association between vitiligo and rheumatic disorders. Differences in comorbid rheumatic disorders by age group and sex suggest the need for patient‐specific approaches. Careful consideration of rheumatic disorders is required for the proper management of comorbidities in vitiligo patients.